Common conditions include: Classical Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Alex Herrera is a Hematologist and a Hematologist Oncology expert in Duarte, CA. Herrera has been practicing medicine for over 14 years and is rated as an Elite expert by MediFind in the treatment of Hodgkin Lymphoma. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Herrera is currently accepting new patients.
Kara Kelly is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Buffalo, New York. Kelly has been practicing medicine for over 34 years and is rated as an Elite expert by MediFind in the treatment of Hodgkin Lymphoma. She is also highly rated in 5 other conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Bone Marrow Transplant. Kelly is currently accepting new patients.
Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Smith has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Hodgkin Lymphoma. She is also highly rated in 34 other conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Smith is currently accepting new patients.
Summary: This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intens...
Summary: This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.